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727Abstracts
sonal interviews with physicians. RESULTS: Prescriptions
for 276 patients (66% women), average age 56 years
(18–88), were collected from 20 specialists. A total of 249
patients had RA (90%), 15 OA (5%) and 12 both (4%).
Fifty-three percent were celecoxib prescriptions, 47%
rofecoxib. Eighty-four percent of 117 rofecoxib prescrip-
tions to RA patients were of 25mg strength. Of these,
95% were dosed 1 ¥ 1 and the average daily number of
tablets was 1.05. Ninety-four percent of 132 celecoxib
prescriptions to RA patients were of 200mg strength. 
Of these, 68% were dosed 1 ¥ 2, and the average daily
number of tablets was 1.86. The average weighted cost
per day for celecoxib was NOK 16.75, and 11.78 for
rofecoxib (pharmacy selling prices). CONCLUSION:
This study by itself does not allow for an assessment of
the drugs’ relative cost-effectiveness. However, the pre-
scription pattern observed among specialists for reim-
bursed cox-2 inhibitors for RA patients indicates a higher
daily drug cost for celecoxib than for rofecoxib.
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OBJECTIVE: Variability in dosing of biologic agents
among patients with rheumatoid arthritis (RA), and asso-
ciated economic impact, is of great interest to payers and
providers. We examined dosing patterns for patients with
RA who were newly treated with inﬂiximab or etanercept
as well as corresponding 1-year costs of care.
METHODS: Integrated pharmacy and medical claims
data were obtained from 61 U.S. health plans. Patients
with a diagnosis of RA who were newly treated with
inﬂiximab or etanercept from July 1999 to June 2002
were selected. Among inﬂiximab patients, a maintenance
number of vials was determined after the “loading
period” (2–3 infusions); those with ≥2 occurrences of an
increase in vials or an interval between infusions of <49
days were considered to have had escalated. For etaner-
cept patients, a maintenance dose was measured on the
second prescription based on the average daily dose dis-
pensed (in mg); those with ≥2 instances of increased
average doses were considered to have escalated their
dose. RA-related costs at one year post-initiation were
examined; statistical comparisons were made using gen-
eralized linear models with a gamma distribution.
RESULTS: A total of 1548 patients were identiﬁed (n =
598 and 950 for inﬂiximab and etanercept respectively).
Inﬂiximab recipients were somewhat older (50.5 vs. 46.6
years for etanercept). Nearly 60% of inﬂiximab patients
experienced an increase in dose at one year, compared to
18% of patients new to etanercept. Inﬂiximab patients
who experienced a dose increase had signiﬁcantly higher
annual RA-related costs than those with no increase
($20,915 vs. $16,713; p < 0.0001). Costs among etaner-
cept patients did not substantially differ based on dose
escalation ($14,482 vs. $13,866 respectively). CON-
CLUSIONS: Patients new to inﬂiximab had much higher
rates of dose escalation relative to etanercept recipients.
These dose increases resulted in signiﬁcantly higher
medical costs at one year.
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OBJECTIVE: This study aims at translating and adapt-
ing the EQ-5D cross-culturally into Korean (KEQ-5D),
and evaluating its reliability and validity among patients
with various rheumatic diseases. METHODS: The EQ-
5D was translated into Korean by 2 translators and back
into English by another 2 translators. Then lay assessment
was done according to the EuroQol Group’s translation
guidelines. Based on the repeated measure data of 65
patients with rheumatoid arthritis (RA), we examined
test-retest reliability by intra-class correlation (ICC), and
responsiveness by effect size and t-statistic. To evaluate
validity, we recruited 100 patients with RA, 103 with
osteoarthritis (OA), 111 with systemic lupus erythemtous
(SLE), 104 with ﬁbromyalgia syndrome (FMS), and 90
with ankylosing spondylitis (AS). For concurrent validity,
we explored correlation between the KEQ-5D and KEQ-
VAS (visual analog scale), KSF-36 global, utility measures
such as time-trade off (TTO) and standard gamble
(SGM), and disease-speciﬁc measures, including KHAQ
and for RA, KWOMAC for OA, SLEDAI and SLICC for
SLE, KFIQ for FMS, and KBASFI for AS. RESULTS: Test-
retest reliability measured by ICC was 0.635. The effect
size was 0.683. Correlations with KEQ-VAS and SF-36
global were signiﬁcant, however those with TTO and
SGM were not. Correlations with disease-speciﬁc mea-
sures were all signiﬁcant except for SLEAI and SLICC 
in SLE, ranging from -0.477 to -0.603. Correlations
between physical domains of KEQ-5D and KSF-36P were
higher those with KSF-36M, on the contrary, correlation
between anxiety/depression and KSF-36M was higher
than that with KSF-36P in both overall and disease-
speciﬁc analysis. CONCLUSION: These ﬁndings indi-
cated that KEQ-5D had stability and responsiveness, and
moreover, criterion and construct validity were satisfac-
tory. We concluded that KEQ-5D could be applied to
Korean patients with various rheumatic diseases.
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